Anti-Amnesic and Neuroprotective Effects of Fluoroethylnormemantine in a Pharmacological Mouse Model of Alzheimer’s Disease

Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease

(2019) D. Allan Butterfield et al.   NATURE REVIEWS NEUROSCIENCE

Neuroprotection in non-transgenic and transgenic mouse models of Alzheimer's disease by positive modulation of σ1 receptors

(2019) Tangui Maurice et al.   PHARMACOLOGICAL RESEARCH

The Concentration of Memantine in the Cerebrospinal Fluid of Alzheimer’s Disease Patients and Its Consequence to Oxidative Stress Biomarkers

(2019) Martin Valis et al.   Frontiers in Pharmacology

Memantine for the Treatment of Dementia: A Review on its Current and Future Applications

(2018) Jaume Folch et al.   JOURNAL OF ALZHEIMERS DISEASE

Peripheral and Central Effects of Memantine in a Mixed Preclinical Mice Model of Obesity and Familial Alzheimer’s Disease

(2018) Miren Ettcheto et al.   MOLECULAR NEUROBIOLOGY

Topographical memory analyzed in mice using the Hamlet test, a novel complex maze

(2018) Lucie Crouzier et al.   NEUROBIOLOGY OF LEARNING AND MEMORY

Evaluation of [ 18 F]FNM biodistribution and dosimetry based on whole-body PET imaging of rats

(2018) Anne-Sophie Salabert et al.   NUCLEAR MEDICINE AND BIOLOGY

Role of Glutamate and NMDA Receptors in Alzheimer’s Disease

(2017) Rui Wang et al.   JOURNAL OF ALZHEIMERS DISEASE

Alzheimer’s Disease: Past, Present, and Future

(2017) Mark W. Bondi et al.   JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY

Cognitive Decline in Neuronal Aging and Alzheimer's Disease: Role of NMDA Receptors and Associated Proteins

(2017) Jesús Avila et al.   Frontiers in Neuroscience

Protection by sigma-1 receptor agonists is synergic with donepezil, but not with memantine, in a mouse model of amyloid-induced memory impairments

(2016) Tangui Maurice   BEHAVIOURAL BRAIN RESEARCH

Pharmacotherapeutic strategies in the treatment of severe Alzheimer’s disease

(2016) William James Deardorff et al.   EXPERT OPINION ON PHARMACOTHERAPY

An Intranasal Formulation of Erythropoietin (Neuro-EPO) Prevents Memory Deficits and Amyloid Toxicity in the APPSwe Transgenic Mouse Model of Alzheimer’s Disease

(2016) Yamila Rodríguez Cruz et al.   JOURNAL OF ALZHEIMERS DISEASE

Radiolabeling of [18F]-fluoroethylnormemantine and initial in vivo evaluation of this innovative PET tracer for imaging the PCP sites of NMDA receptors

(2015) Anne-Sophie Salabert et al.   NUCLEAR MEDICINE AND BIOLOGY

Mitochondrial protection by the mixed muscarinic/σ1 ligand ANAVEX2-73, a tetrahydrofuran derivative, in Aβ25–35 peptide-injected mice, a nontransgenic Alzheimer’s disease model

(2015) Valentine Lahmy et al.   Frontiers in Cellular Neuroscience

Memantine Attenuates Alzheimer’s Disease-Like Pathology and Cognitive Impairment

(2015) Xiaochuan Wang et al.   PLoS One

Combining two repurposed drugs as a promising approach for Alzheimer's disease therapy

(2015) Ilya Chumakov et al.   Scientific Reports

Memantine improves spatial learning and memory impairments by regulating NGF signaling in APP/PS1 transgenic mice

(2014) M.Y. Liu et al.   NEUROSCIENCE

Amyloid-β and Tau

(2014) George S. Bloom   JAMA Neurology

Intranasal formulation of erythropoietin (EPO) showed potent protective activity against amyloid toxicity in the Aβ25-35 non-transgenic mouse model of Alzheimer’s disease

(2013) Tangui Maurice et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Dysfunctional synapse in Alzheimer's disease – A focus on NMDA receptors

(2013) Sandra I. Mota et al.   NEUROPHARMACOLOGY

Blockade of Tau Hyperphosphorylation and Aβ1–42 Generation by the Aminotetrahydrofuran Derivative ANAVEX2-73, a Mixed Muscarinic and σ1 Receptor Agonist, in a Nontransgenic Mouse Model of Alzheimer’s Disease

(2013) Valentine Lahmy et al.   NEUROPSYCHOPHARMACOLOGY

The γ-secretase inhibitor 2-[(1R)-1-[(4-chlorophenyl)sulfonyl](2,5-difluorophenyl) amino]ethyl-5-fluorobenzenebutanoic acid (BMS-299897) alleviates Aβ1–42 seeding and short-term memory deficits in the Aβ25–35 mouse model of Alzheimer's disease

(2012) Johann Meunier et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs

(2011) Salvatore Salomone et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Combination Therapy for Alzheimerʼs Disease

(2011) Laxeshkumar Patel et al.   DRUGS & AGING

Animal research: Reporting in vivo experiments: The ARRIVE guidelines

(2010) Carol Kilkenny et al.   BRITISH JOURNAL OF PHARMACOLOGY

Memantine Preferentially Blocks Extrasynaptic over Synaptic NMDA Receptor Currents in Hippocampal Autapses

(2010) P. Xia et al.   JOURNAL OF NEUROSCIENCE

Anti-amnesic and neuroprotective potentials of the mixed muscarinic receptor/sigma1 (σ1) ligand ANAVEX2-73, a novel aminotetrahydrofuran derivative

(2010) Vanessa Villard et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders

(2010) Giles E. Hardingham et al.   NATURE REVIEWS NEUROSCIENCE

Propagation of Tau Misfolding from the Outside to the Inside of a Cell

(2009) Bess Frost et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Effects of memantine on soluble Αβ25-35-induced changes in peptidergic and glial cells in Alzheimer's disease model rat brain regions

(2009) M. Arif et al.   NEUROSCIENCE

Antiamnesic and Neuroprotective Effects of the Aminotetrahydrofuran Derivative ANAVEX1-41 Against Amyloid β25–35-Induced Toxicity in Mice

(2008) Vanessa Villard et al.   NEUROPSYCHOPHARMACOLOGY

Effects of Memantine on Neuronal Structure and Conditioned Fear in the Tg2576 Mouse Model of Alzheimer's Disease

(2008) Hongxin Dong et al.   NEUROPSYCHOPHARMACOLOGY

The anti-amnesic and neuroprotective effects of donepezil against amyloid β25-35 peptide-induced toxicity in mice involve an interaction with the σ1 receptor

(2006) J Meunier et al.   BRITISH JOURNAL OF PHARMACOLOGY